Two-Year arthritis drug trial shows promise for Long-Term relief
NCT ID NCT04049448
Summary
This study followed 40 patients with moderate to severe rheumatoid arthritis for up to two years to see if the oral medication ABX464 remains safe and effective over time. All participants received the same daily dose of the drug, regardless of whether they received the real medication or a placebo in the earlier study phase. The main goal was to monitor side effects while checking if the treatment helped patients achieve and maintain low disease activity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHR d'Orléans
Orléans, France
-
CHU DE MONTPELLIER - Hôpital Lapeyronie
Montpellier, France
-
CHU de Brest - Hôpital Cavale Blanche
Brest, France
-
CMed Rehabilitációs és Diagnosztikai Központ
Székesfehérvár, Hungary
-
CRU Hungary Ltd.
Miskolc, Hungary
-
ClinicMed Daniluk, Nowak Sp. J.
Bialystok, Poland
-
Cliniques Universitaires Saint-Luc
Brussels, Belgium
-
Complex Medical Centre - Déli Klinika
Budapest, Hungary
-
Medyczne Centrum Hetmańska
Poznan, Poland
-
NZOZ Lecznica MAK-MED S.C.
Nadarzyn, Poland
-
National Institute of Geriatrics
Warsaw, Poland
-
Pratia MCM
Krakow, Poland
-
UZ Gent
Ghent, Belgium
-
Zespół Poradni Specjalistycznych REUMED
Lublin, Poland
Conditions
Explore the condition pages connected to this study.